Radiotheranostics: a roadmap for future development
- PMID: 32135118
- PMCID: PMC7367151
- DOI: 10.1016/S1470-2045(19)30821-6
Radiotheranostics: a roadmap for future development
Abstract
Radiotheranostics, injectable radiopharmaceuticals with antitumour effects, have seen rapid development over the past decade. Although some formulations are already approved for human use, more radiopharmaceuticals will enter clinical practice in the next 5 years, potentially introducing new therapeutic choices for patients. Despite these advances, several challenges remain, including logistics, supply chain, regulatory issues, and education and training. By highlighting active developments in the field, this Review aims to alert practitioners to the value of radiotheranostics and to outline a roadmap for future development. Multidisciplinary approaches in clinical trial design and therapeutic administration will become essential to the continued progress of this evolving therapeutic approach.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests
KH reports personal fees from Bayer, SIRTEX, Adacap, Curium, Endocyte, IPSEN, Siemens Healthineers, GE Healthcare, Amgen, and Novartis; non-financial support from ABX; grants and personal fees from BTG; and stock options (<1% of the company) from Sofie Biosciences, outside the submitted work. MS reports personal fees from GE Healthcare outside the submitted work. JSL reports personal fees from Clarity Pharmaceuticals, Varian Medical Systems, and InVicro; personal fees and other support from pHLIP Technologies; non-financial support from Trace-Ability, Thermo Fisher Scientific, Ground Fluor Pharmaceuticals, AbbVie, and Genentech; other support from Telix Pharmaceuticals, Eli Lilly, Sapience Therapeutics, MabVax Therapeutics, SibTech, ImaginAb, Merck, Bristol-Myers Squibb, Y-mAbs, and Regeneron Pharmaceuticals, outside the submitted work. SBS reports grants from GE Healthcare and Elesta; grants and other support from Johnson & Johnson; personal fees from BTG, XACT Robotics, Endoways, and Adgero; non-financial support from AngioDynamics; personal fees and other support from Aperture Medical; and other support from Immunomedics and Progenics, outside the submitted work. MB attended an advisory board meeting of Merck KGaA (Darmstadt), for which the University of Dresden received a travel grant. He further received funding for his research projects and for educational grants to the University of Dresden by Teutopharma GmbH (2011–2015), IBA (2016), Bayer AG (2016–2018), Merck KGaA (2014–2030), and Medipan GmbH (2014–2018). He is on the supervisory boards of HI-STEM gGmbH for the German Cancer Research Centre (DKFZ, Heidelberg). As a former chair of OncoRay (Dresden) and present CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg), he has been responsible for collaborations with a multitude of companies and institutes worldwide; signed contracts for institutes and staff members for research funding and collaborations with industry and academia; and has been responsible for commercial technology transfer activities of institutes, including the DKFZ-PSMA617 related patent portfolio [WO2015055318 (A1), ANTIGEN (PSMA)] and similar IP portfolios. MB confirms that none of the above funding sources were involved in the preparation of this Review. SSG reports personal fees from AbbVie, Ceremark Pharma, Endra, and Great Point (BVP); other support from Akrotome Imaging, Cellsight Technologies, CytomX Therapeutics, Grail, ImaginAb, MagArray, Nodus Therapeutics, Puretech, RefleXion Medical, SiteOne Therapeutics, Spectrum Dynamics, and Vor Biopharma; and personal fees and other from EARLI, Nines, Nusano, and Vave Health, outside the submitted work. HH reports personal fees from Ion Beam Applications, outside the submitted work. RW reports personal fees from Tarveda Pharmaceuticals and ModeRNA; personal fees and non-financial support from Accure Health and Lumicell; and non-financial support from T2Biosystems (Shareholder), outside the submitted work. BJM declares no competing interests.
Figures




References
-
- Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc 1946; 132: 838–47. - PubMed
-
- Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 2005; 6: 112–17. - PubMed
-
- Baumann M, Krause M, Overgaard J, et al. Radiation oncology in the era of precision medicine. Nat Rev Cancer 2016; 16: 234–49. - PubMed
-
- Kim H, Beack S, Han S, et al. Multifunctional photonic nanomaterials for diagnostic, therapeutic, and theranostic applications. Adv Mater 2018; 30: 30. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous